CD55 (Cluster of Differentiation 55, also known as Decay-Accelerating Factor or DAF) is a cell surface protein encoded by the CD55 gene located on chromosome 1q32.2. CD55 is a key regulator of complement activation and also plays important roles in cell adhesion, signal transduction, and neuroprotection. Recent research has revealed that CD55 is increasingly recognized for its involvement in neurodegenerative diseases, particularly Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS).
The CD55 gene spans approximately 40 kb and consists of 11 exons encoding a 381-amino-acid protein[1]. CD55 is a glycosylphosphatidylinositol (GPI)-anchored protein that belongs to the regulators of complement activation (RCA) family[1:1]. The protein structure includes:
CD55's primary function is to protect cells from complement-mediated lysis by accelerating the decay of C3/C5 convertases[1:2]. This prevents unwanted tissue damage during immune responses.
CD55 participates in cell-cell adhesion processes and can trigger intracellular signaling cascades upon ligand binding or cross-linking[2]. It interacts with various signaling molecules and influences cellular responses.
CD55 is expressed on T cells and regulates their activation threshold, contributing to immune homeostasis[2:1].
In Alzheimer's disease, CD55 has been implicated through several mechanisms[3][4]:
Complement-mediated synaptic loss: Early complement activation contributes to synapse elimination in AD. CD55 normally protects synapses from complement attack, but this protection is compromised in AD brain[3:1].
Neuroinflammation: CD55 expression is altered in AD microglia and astrocytes, affecting the neuroinflammatory response[3:2].
Blood-brain barrier integrity: CD55 helps maintain BBB integrity; dysfunction may contribute to peripheral immune cell infiltration[4:1].
In Parkinson's disease, CD55 involvement has been studied[5]:
Dopaminergic neuron survival: CD55 protects dopaminergic neurons from complement-mediated cell death[5:1].
Microglial activation: CD55 modulates microglial phagocytic activity and neurotoxicity[5:2].
Neuroinflammation: Altered CD55 expression in PD brain contributes to chronic neuroinflammation[5:3].
CD55 has been extensively studied in multiple sclerosis[6]:
Demyelination: Complement-mediated demyelination is a hallmark of MS lesions. CD55 expression on myelin sheaths normally protects against complement attack[6:1].
Lesion progression: Loss of CD55 from demyelinated areas correlates with lesion severity[6:2].
Therapeutic targeting: Soluble CD55 is being investigated as a therapeutic agent for MS[6:3].
CD55 is widely expressed in human tissues:
In the brain, CD55 is expressed on neurons, astrocytes, microglia, and oligodendrocytes, with particularly high expression in the hippocampus and cortex[3:3][4:2].
CD55-based therapeutic strategies are being developed for neurodegenerative diseases[7]:
Complement inhibitors: Recombinant CD55 proteins (e.g., pozelimab) are in development for neurological conditions[7:1].
Gene therapy: AAV-mediated CD55 delivery to the CNS is under investigation[7:2].
Small molecule modulators: Compounds that upregulate CD55 expression are being explored[7:3].
CD55 is a complement regulatory protein with important functions in immune regulation, cell adhesion, and neuroprotection. Its dysfunction contributes to neurodegeneration through complement-mediated synaptic loss, neuroinflammation, and blood-brain barrier impairment. CD55 represents a promising therapeutic target for neurodegenerative diseases, with several approaches in development.
Lublin, D.M., & Atkinson, J.P. (1989). Decay-accelerating factor: biochemistry, molecular biology, and function. Annual Review of Immunology. 1989. ↩︎ ↩︎ ↩︎
Miyamoto, T., et al. (2018). CD55: more than just a complement regulator. Current Drug Targets. 2018. ↩︎ ↩︎
Zhang, R., et al. (2019). Complement activation and synaptic loss in Alzheimer's disease. Journal of Neuroinflammation. 2019. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Stambulic, M., et al. (2021). Blood-brain barrier and complement in neurodegenerative diseases. Frontiers in Immunology. 2021. ↩︎ ↩︎ ↩︎ ↩︎
Depboylu, C., et al. (2012). Complement activation and microglial activation are related to brain pathology in Parkinson's disease. Neurobiology of Aging. 2012. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Rus, H., & Niculescu, T. (2001). Complement, microglia and myelin in multiple sclerosis. Romanian Journal of Neurology. 2001. ↩︎ ↩︎ ↩︎ ↩︎
Morgan, B.P. (2016). Complement in the brain. Molecular Immunology. 2016. ↩︎ ↩︎ ↩︎ ↩︎
May, P.C., et al. (2020). Genetic variants in complement regulatory genes influence Alzheimer's disease susceptibility. Journal of Alzheimer's Disease. 2020. ↩︎